Clinical Trial Update: TGRX-678 US Phase I for Subjects with Refractory or Advanced Chronic Myelogenous Leukemia [Phase 1]

View source ↗

Summary

A US Phase I trial evaluating TGRX-678 for patients with refractory or advanced chronic myelogenous leukemia is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelogenous Leukemia

Drugs mentioned

• TGRX-678

Snippet

Sponsor: Shenzhen TargetRx Co., Ltd. | Conditions: Chronic Myelogenous Leukemia | Phase 1 | Status: RECRUITING